April, 2024

article thumbnail

What we’re starting to learn about H5N1 in cows, and the risk to people

STAT

The H5N1 bird flu virus has been around for decades, and the damage it wreaks on chickens and other poultry is well documented. But the recent discovery that the virus has jumped into dairy cattle — whose udders seem to be where the virus either infects or migrates to — has dumbfounded scientists and agricultural authorities. Questions for which there are pretty clear answers when it comes to birds are suddenly unsettled science in cows.

article thumbnail

As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene

PharmaVoice

AMR is a growing threat, but with little financial incentive to pick up the torch, government and nonprofit collaborations are keeping the R&D flames burning.

325
325
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Cost of developing new drugs may be far lower than industry claims, trial reveals

The Guardian - Pharmaceutical Industry

Exclusive: MSF calls for transparency after its bill for a trial of TB treatment came to a fraction of the billions claimed by pharmaceutical companies Doctors have for the first time released details of their spending on a major clinical trial, demonstrating that the true cost of developing a medicine may be far less than the billions of dollars claimed by the pharmaceutical industry.

article thumbnail

Psychiatry drugs finally have pharma’s attention. Can they keep it?

BioPharma Dive

Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.

136
136
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Comparison Of Rebyota Versus Vowst: A Study Table To Help You Compare Fecal Microbiota Therapies

ID Stewardship

In this article a comparison of Rebyota versus Vowst is provided, to help learners differentiate these two fecal microbiota therapies. Authored by: Natalie Boyer, Pharm.D. Candidate 2025 Mentored by: Christina G. O’Connor, Pharm.D., PharmD, BCPS, BCIDP, AAHIV-M Disclaimer : This text and table is intended for use as a study tool to assist people learning pharmacotherapy of recurrent Clostridioides difficile infections (rCDI).

Hospitals 132
article thumbnail

Pfizer and BioNTech commence legal action against Moderna in UK court

Pharmaceutical Technology

Pfizer and its Germany partner BioNTech have urged London’s High Court to invalidate competitor Moderna's patents over technology instrumental in the Covid-19 vaccines development as the latest phase of a global legal fight that started yesterday (23 April), reported Reuters.

Vaccines 130

More Trending

article thumbnail

Traditional gene therapies are uber-niche. Ocugen hopes to change that.

PharmaVoice

The biotech is developing a ‘gene-agnostic’ approach to expand the patient pool for gene therapies.

363
363
article thumbnail

Spotlight on kidney disease: Driving change for patients

pharmaphorum

Explore the latest advancements and initiatives in kidney disease research, driving change for patients with kidney conditions. Learn more about the current research landscape and potential breakthroughs in treatment from Kidney Research UK.

126
126
article thumbnail

Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo

BioPharma Dive

It’s “early innings” in the obesity drug race, said Metsera CEO Clive Meanwell, whose company has acquired a portfolio of medicines it aims to test in combination.

126
126
article thumbnail

Pharmacy First: Top tips for managing non-bullous impetigo

The Pharmacist

Most community pharmacies in England now running the Pharmacy First service which enables them to diagnose and treat seven specific conditions. Under the service, pharmacists can prescribe set medications where appropriate, without recourse to a GP. This will hopefully reduce some of the current pressures on general practice. This series of guides assumes that pharmacists […] The post Pharmacy First: Top tips for managing non-bullous impetigo appeared first on The Pharmacist.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

EMA Says No Evidence for Link between Type 2 Diabetes Drugs and Suicidal Tendencies

PharmaTech

The agency’s risk assessment committee has concluded that available evidence has not been found that supports a causal association between glucagon-like peptide-1 receptor agonists and self-harming thoughts and actions.

Diabetes 119
article thumbnail

Opinion: Medical students lose in the research arms race for residency slots

STAT

“Going to medical Spanish class really isn’t worth my time. I’d rather use the time to do research,” one of my classmates told me during the first week of my first year of medical school. Such a comment was my introduction to the publish-or-perish environment that is increasingly pervasive amongst medical students. Before then, I had known publish-or-perish as something for those seeking tenure at universities.

article thumbnail

Next-gen menopause treatments have blockbuster potential. Can women, doctors and payers be convinced?

PharmaVoice

The market is huge, but will companies overcome the triple hurdles of payer hesitance, prescriber reluctance and sluggish consumer demand?

306
306
article thumbnail

Embracing new delivery models in the UK

pharmaphorum

Learn about the exciting developments in healthcare delivery in the UK, including the IDX2 trial, NHS initiatives, NIHR research, and the Digital Delivery Team. Explore how these new delivery models are revolutionising healthcare.

124
124
article thumbnail

New postpartum depression drugs are here. Diagnosis, treatment hurdles still stand in the way.

BioPharma Dive

The first medicine approved for PPD, Sage’s Zulresso, never gained traction. The company is in the midst of launching its second, but long-standing challenges could slow uptake.

126
126
article thumbnail

AstraZeneca’s Lynparza to dominate PARP inhibitors market with $4 bn in sales by 2027: GlobalData

Express Pharma

In 2014, the FDA approved the first (adenosine diphosphate-ribose) polymerase (PARP) inhibitor AstraZeneca /Merck’s Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients who have received three or more prior lines of chemotherapy. Since then, the PARP inhibitors market has made significant strides, but Lynparza maintains its dominance with projected global sales of $4 billion by 2027, according to an analyst consensus forecast by GlobalData.

article thumbnail

Interview: Thermo Fisher Scientific's Sarah Englert on opening the doors to its new innovation hub

Outsourcing Pharma

Yesterday, Thermo Fisher Scientific opened its first Innovation Lab in Center Valley, Pennsylvania., as a space where partners can come together to collaborate, innovate, and ideate on solutions to the biggest clinical supply chain pain points.

116
116
article thumbnail

With younger women getting breast cancer, national panel lowers mammogram screening age to 40

STAT

A national advisory panel significantly lowered the age recommendations for screening mammography on Tuesday, saying that all women should start breast cancer screening at age 40, rather than 50, and continue every other year until age 74. The previous recommendations from the panel, the United States Preventive Services Task Force, suggested that women make an individual choice on getting mammography from ages 40 to 49.

362
362
article thumbnail

With a rise in animal-human organ transplants, a drugmaker aims for a new standard of care

PharmaVoice

Eledon Therapeutics is developing a drug that could facilitate organ transplants from animals to humans as the procedure gains steam.

313
313
article thumbnail

12 Questions with Dr Jay Shah

pharmaphorum

Get to know Dr Jay Shah, a prominent figure in the field of cardiovascular medicine, as he answers 12 intriguing questions about his role as Chief Medical Officer at Aktiia and his insights into the field.

124
124
article thumbnail

Vertex begins bid for US approval of non-opioid painkiller

BioPharma Dive

The start of a so-called rolling review formally begins an FDA evaluation of a closely watched drug that’s important to the biotech’s future, but faces questions about its sales potential.

121
121
article thumbnail

Measles cases in London now in line with West Midlands

The Pharmacist

A rise in measles cases in London has brought the capital in line with the number of cases recorded in the West Midlands – the initial hotspot for the virus. This comes as the rise in cases appears to be plateauing across the country and as a national catch-up campaign has increased vaccination uptake over […] The post Measles cases in London now in line with West Midlands appeared first on The Pharmacist.

Vaccines 116
article thumbnail

ICR collaboration forms national NHS patient database registry for Lynch syndrome patients

Pharma Times

The genetic condition affects one in 279 people in England and significantly increases cancer risk

149
149
article thumbnail

Early tests of H5N1 prevalence in milk suggest U.S. bird flu outbreak in cows is widespread

STAT

Andrew Bowman, a veterinary epidemiologist at Ohio State University, had a hunch. He had been struck by the huge amounts of H5N1 virus he’d seen in milk from cows infected with the bird flu and thought that at least some virus was getting off of farms and going downstream — onto store shelves. He knew the Food and Drug Administration was working on its own national survey of the milk supply.

364
364
article thumbnail

Behind the ‘encouraging’ new results for Amylyx’s beleaguered drug

PharmaVoice

Where Amylyx ultimately failed in ALS, it could prevail in a rare disease. The doctor leading this research explains why.

299
299
article thumbnail

How do we unlock the potential of digital health?

pharmaphorum

Unlock the power of digital health through AI and clinical advancements. Learn how these technologies are shaping the future of healthcare and how to harness their potential.

124
124
article thumbnail

Ultragenyx says Angelman therapy is working, but safety questions remain

BioPharma Dive

Treatment appeared to result in functional and cognitive gains in people with the neurological disorder. Three participants experienced lower extremity weakness, however.

122
122
article thumbnail

Outrun Therapeutics announces launch with $10m seed funding

Pharmaceutical Technology

Outrun Therapeutics announced its launch with $10m seed funding to advance a protein stabilisation pipeline focused on E3 ligase inhibitors.

129
129
article thumbnail

Study suggests tumour microenvironments could predict cancer progression

Pharma Times

NSCLC is the most common type of lung cancer and is responsible for up to 85% of all cases

151
151
article thumbnail

Massive amounts of H5N1 vaccine would be needed if there’s a bird flu pandemic. Can we make enough?

STAT

The unsettling reality of H5N1 bird flu circulating in dairy cow herds in multiple parts of the United States is raising anxiety levels about whether this dangerous virus, which has haunted the sleep of people who worry about influenza pandemics for more than 20 years, could be on a path to acquiring the ability to easily infect people. To be clear, there is no evidence that this is currently the case — the sole confirmed human case reported in Texas three weeks ago was in a farm worker w

Vaccines 363
article thumbnail

Vistagen’s on-demand nasal spray could provide a novel option for social anxiety

PharmaVoice

The fast-acting medication is one of a few new approaches being tested for the crippling condition.

321
321
article thumbnail

AI in Medical Communications: Revolutionising the present, redefining the future

pharmaphorum

Discover how AI is transforming medical communications and reshaping the future of healthcare. Learn about the latest trends, technologies, and advancements in this rapidly evolving field.

article thumbnail

5 FDA decisions to watch in the second quarter

BioPharma Dive

The FDA could soon expand use of two multiple myeloma cell therapies as well as a top-selling medicine from Sanofi and Regeneron, while Pfizer’s years of gene therapy work might finally pay dividends.

120
120
article thumbnail

ESCMID 2024: Using AI in infection prevention and control

Pharmaceutical Technology

Artificial intelligence tools can be used for infection control through facial recognition systems designed to identify proper face mask use within hospitals.

Hospitals 119
article thumbnail

FDA Grants Breakthrough Device Designation to Assay Supporting Earlier Diagnosis of Alzheimer Disease

Pharmacy Times

If approved, the test could provide more timely and accurate diagnosis, hopefully mitigating the impact of Alzheimer disease (AD) on individuals and the community.

70